Efficacy of Antenatal Steroids in Reducing Respiratory Morbidities in Late Preterm Infants

NCT ID: NCT01206946

Last Updated: 2011-06-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

700 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis of the study is that administration of antenatal steroid to women at high risk of preterm birth after 34 weeks of gestation would reduce the risk of respiratory complications, specifically Respiratory Distress Syndrome (RDS) or Transient Tachypnea of the Newborn (TTN) in late preterm babies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome, Newborn Transient Tachypnea of the Newborn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antenatal steroids

Group Type EXPERIMENTAL

Betamethasone

Intervention Type DRUG

A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)

Normal saline

Group Type PLACEBO_COMPARATOR

Normal Saline

Intervention Type OTHER

Two doses of 2ml of normal saline given at 24 hourly intervals

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Betamethasone

A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)

Intervention Type DRUG

Normal Saline

Two doses of 2ml of normal saline given at 24 hourly intervals

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women between 34 0/7- 36 6/7 weeks of gestation
* High risk of preterm birth

Exclusion Criteria

* Multiple births
* Fetal congenital malformations
* A course of steroids within 2 weeks of randomization
* Multiple courses of steroids
* Chorioamnionitis
* Non reassuring fetal heart rate
* Obstetrical indication of delivery
* Active bleeding
* Pregnancy related hypertensive disorders
* Uncontrolled diabetes
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American University of Beirut Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

American University of Beirut Medical Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Khalid Yunis, MD

Role: PRINCIPAL_INVESTIGATOR

American University of Beirut Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

American University of Beirut Medical Center

Beirut, , Lebanon

Site Status RECRUITING

Bahman Hospital

Beirut, , Lebanon

Site Status RECRUITING

Hotel Dieu de France

Beirut, , Lebanon

Site Status NOT_YET_RECRUITING

Rafik Hariri University Hospital

Beirut, , Lebanon

Site Status RECRUITING

St Georges Hospital- University Medical Center

Beirut, , Lebanon

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Lebanon

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Khalid Yunis, MD

Role: CONTACT

961-1-350000 ext. 5538

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PED.KY.11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dexamethasone for Preterm Labour
NCT01697098 COMPLETED PHASE2
Hydrocortisone for BPD
NCT01353313 COMPLETED PHASE3
Odors to Insufflate Life
NCT02851979 TERMINATED NA